Sanofi Inaugurates C$925M Toronto Flu Vaccine Facility to Make Fluzone High-Dose
核心洞察
Sanofi inaugurated the Charles Best Building in Toronto, a C$925 million influenza (搜索) vaccine manufacturing facility that is the largest biomanufacturing investment in Canadian history.
The facility will produce Fluzone High-Dose, Sanofi's influenza (搜索) vaccine containing four times the antigen of standard-dose vaccines and indicated for adults 65 and older.
Production is expected to begin in early 2027, pending regulatory approval, in preparation for the 2027-28 influenza (搜索) season, with about 300 skilled jobs created.
Sanofi has inaugurated the Charles Best Building, a new influenza (搜索) vaccine manufacturing facility on its 52-acre Toronto campus, following a C$925 million investment that the company describes as the single-largest investment in a biomanufacturing facility in Canadian history. The facility is now fully operational and, pending regulatory approval, is expected to begin production in early 2027 in preparation for the 2027-28 influenza season.
The building will manufacture Fluzone High-Dose, Sanofi's influenza (搜索) vaccine indicated for adults 65 years of age and older. According to the product monograph, the vaccine contains four times the amount of antigen compared to standard-dose influenza vaccines and is designed specifically to provide protection for that older population. Sanofi notes that influenza poses a serious threat to older Canadians, who account for the majority of flu-related hospitalizations each year.
Public Funding and Partnership
The C$925 million investment includes C$415 million in support from the Government of Canada (搜索) and C$55 million from the Government of Ontario (搜索). The expansion was developed in partnership with the Government of Canada, the Province of Ontario and the City of Toronto (搜索), and is intended to strengthen Canada's vaccine biomanufacturing capabilities and preparedness for future influenza (搜索) pandemics.
"Sanofi's continued investment in Canada's operations spans R&D, production and delivery of vaccines and medicines to protect Canadians," said James Guy, Canada Country Lead at Sanofi. "Today marks a strategic milestone for Sanofi and we remain committed to working with the government to ensure Canadians have timely and reliable access to the innovations that improve, and save, lives."
Mélanie Joly, Canada's Minister of Industry, called the investment "a strong vote of confidence in Canada's life sciences sector and in our workers," adding that the facility will strengthen domestic industrial vaccine capacity, create quality jobs and reinforce economic security. Marjorie Michel, Canada's Minister of Health, said the inauguration strengthens Canada's pharmaceutical sovereignty and helps protect the health of Canadians.
Ontario Premier Doug Ford said the province's investment plan has brought in over $235 billion in investments, including the Sanofi project, creating more than one million new jobs for Ontario workers. Toronto Mayor Olivia Chow described the facility as a major milestone in public health preparedness for Canada.
Manufacturing Footprint and Capacity
The Charles Best Building broke ground in 2021 and adds end-to-end vaccine manufacturing capacity to Sanofi's Toronto campus, which has developed into a major vaccine research, development and manufacturing hub. Vaccines produced at the campus are distributed to more than 60 countries worldwide. The building is named after Dr. Charles Best, co-discoverer of insulin and an early medical director at what is now the Sanofi Toronto Campus.
The expansion is expected to create approximately 300 highly skilled jobs in advanced biomanufacturing. Sanofi is the largest biopharmaceutical manufacturer in Canada, with more than 2,000 employees and operations spanning research and development, manufacturing and delivery of vaccines and medicines. The company invests 20% of its revenue annually in biopharma research and said it is on track to deliver more than $2 billion in new infrastructure investments in Canada by 2028, including a recently announced $294 million investment to expand its AI Centre of Excellence in Toronto.